Drug intelligence / Profile preview

JB-132

Development stage: Preclinical
Lead developer: Junten Bio

Overview

JB-132 is a preclinical drug candidate being developed by Junten Bio, a biotechnology company focused on establishing immune tolerance in organ transplantation. The drug is part of a pipeline aimed at preventing graft rejection and reducing the dependency on long-term immunosuppressive medications. While specific details regarding its modality and molecular targets are not yet publicly available, Junten Bio's platform primarily utilizes inducible inhibitory T-cells and specialized antibody drugs to modulate the immune response in transplant recipients. JB-132 is currently being investigated for its potential application in organ transplantation and may eventually be explored for other intractable diseases caused by hyperimmune reactions.

Beyond the preview

Go deeper on JB-132.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JB-132.

Explore the full profile